pre-IPO PHARMA

COMPANY OVERVIEW

Formula Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing a proprietary, next generation Chimeric Antigen Receptor (CAR) immunotherapy platform. Formula’s technology platform offers important opportunities for improvements to existing CAR approaches, with the objective to significantly increase patient access, clinical benefit potential, and cost-effectiveness of manufacturing.


LOCATION

  • Berwyn, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    http://www.formulapharma.com/


    CAREER WEBSITE

    http://www.formulapharma.com/careers/default.asp


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Apr 30, 2020

    CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.


    Sep 18, 2017

    Formula Pharmaceuticals Announces Initiation of the First Clinical Trial for Allogeneic CIK-CAR Cancer Immunotherapy


    Apr 28, 2017


    May 5, 2016

    CORRECTING and REPLACING Formula Pharmaceuticals Appoints Malcolm K. Brenner, MD, PhD to Its Scientific Advisory Board


    Feb 22, 2016

    Formula Pharmaceuticals and Rockland Immunochemicals Enter Into a Collaboration To Develop C.I.K. CAR Immunotherapy Pipeline for the Treatment of Cancer


    For More Press Releases


    Google Analytics Alternative